Molecular Cytogenetics Market Size, Share and Forecast Report by 2023

The increasing cases of cancer, usage of pharmacogenomics for drug development and disease management, enhancements in molecular cytogenetics and its expanding application in agriculture, requirement for predicting chromosomal abnormalities based on genes, and surging geriatric population are driving the usage of molecular cytogenetics. From $1.8 billion in 2017, the molecular cytogenetics market size is projected to reach $3.3 billion by 2023, at a 9.9% CAGR during 2018–2023 (forecast period). The term refers to the study of chromosomes, their structure, and location and function in cells, in order to detect inherited diseases.

Based on application, the divisions of the market are personalized medicine, genetic disorders, cancer, and others. Among these, cancer held the largest value share, of 41.9%, in 2017, owing to the rising prevalence of the disorder, which is leading to the increasing usage of molecular cytogenetics for early detection. Additionally, studying patients’ genes also helps determine if they qualify for immunotherapy. Technologies such as gene expression profiling, fluorescence in-situ hybridization (FISH), single-nucleotide polymorphism (SNP), and comparative genomic hybridization (CGH) offer data regarding molecular signatures, which can lead to the disease.

Another important reason behind the growth of the molecular cytogenetics market is the advancements in technologies. These techniques help analyze the 3D organization of genomes and the genetic changes that lead to various diseases. Enhancements in FISH have led to more-precise molecular diagnostics and research, while array-comparative genomic hybridization is helping bring cytogenetics and molecular biology closer. Additionally, the automation of the testing process saves cost and time for every case and provides better patient care and diagnostic efficiency, thereby becoming increasingly popular in research labs and medical centers.

North America led the molecular cytogenetics market in 2017, with a revenue share of 46.4%. This is attributed to the rise in the number of people suffering from cancer and other genetic disorders, better healthcare infrastructure than in other regions, and usage of improved technologies, including next-generation sequencing. With an 11.8% CAGR, Asia-Pacific would display the fastest industry prosperity during the forecast period, as the market here is untapped, the population is high, and global market players are entering it.

Hence, as cancer becomes an even bigger problem than presently and the agrarian community looks for ways to improve the crop, the usage of molecular cytogenetics would increase further.

Report this Page